Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function-Reference-Cited by-同舟云学术

Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function

Published:2023-11-12 Issue:2 Volume:20 Page:185-196
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Fanaropoulou Nina Maria¹,Tsatsani Georgia C.¹,Koufakis Theocharis²^ORCID,Kotsa Kalliopi³

Affiliation:

1. School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

2. Second Propaedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

3. Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2023.2281990

Reference69 articles.

1. New Frontiers in the Treatment of Type 1 Diabetes

2. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010–2017

3. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control

4. Incidence and trend of type 1 diabetes and the underlying environmental determinants

5. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of Genome-Editing Technologies for Type 1 Diabetes;International Journal of Molecular Sciences;2023-12-26